Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Neurofibromatosis type I (NF1) is a common dominantly inherited disorder, and one of the most common of the RASopathies. Most individuals with NF1 develop plexiform neurofibromas and cutaneous neurofibromas, nerve tumors caused by NF1 loss of function in Schwann cells. Cell culture models and mouse models of NF1 are being used to test drug efficacy in preclinical trials, which led to Food and Drug Administration approval for use of MEK inhibitors to shrink most inoperable plexiform neurofibromas. This article details methods used for testing in preclinical models, and outlines newer models that may identify additional, curative, strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pcl.2023.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic Review: Biopsychosocial Factors Related to Attention-Deficit/Hyperactivity Disorder in Children/Adolescents with Neurofibromatosis Type 1.
Neurosci Biobehav Rev
September 2025
Murdoch Children's Research Institute, Melbourne, Australia; Department of Pediatrics, University of Melbourne, Melbourne, Australia.
This systematic review was conducted to provide a comprehensive summary of biopsychosocial factors associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with Neurofibromatosis Type 1 (NF1), and identify key limitations and gaps in the current literature. Systematic literature searches were conducted in Scopus, PsycINFO, Web of Science, PubMed, and ProQuest Dissertations and Theses Global in March 2024. The searches identified 2,345 unique articles.
View Article and Find Full Text PDFCord Tethering By Plexiform Neurofibroma: A Rare Cause of Neurological Deficit in Dystrophic Scoliosis: A Case Report.
JBJS Case Connect
July 2025
Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh, India.
Case: A 12-year-old girl with neurofibromatosis type 1 presented with progressive thoracic scoliosis and neurological deficit. Imaging revealed a dystrophic curve, dorsal syrinx, and tethering of the cord by a plexiform neurofibroma arising from the T7 dorsal ramus. She underwent staged surgery: detethering through T6-T8 laminectomy, followed by posterior spinal deformity correction with Schwab type 2 osteotomies and instrumentation.
View Article and Find Full Text PDFSocially oriented attention in young children with neurofibromatosis type 1: An eye-tracking study.
Dev Med Child Neurol
September 2025
Murdoch Children's Research Institute, Parkville, VIC, Australia.
Aim: To examine visual engagement to social stimuli and response to joint attention in young children with neurofibromatosis type 1 (NF1) and typically developing peers (controls).
Method: Forty-five preschool children were studied cross-sectionally (mean age [SD] = 4 years 3 months [10 months]), 25 with NF1 and 20 typically developing controls. Participants passively viewed two eye-tracking paradigms.
Surgical Measures Improving Functional Limitations of the Masticatory System, Aesthetic Deficits, and Skeletal Malformations in Neurofibromatosis Type 1-associated Hemifacial Diffuse Plexiform Neurofibroma Complicated by Rapidly Growing Midfacial Peripheral Nerve Sheath Tumor.
Cancer Diagn Progn
September 2025
Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
Background/aim: Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of multiple tumors, including plexiform neurofibromas (PNFs), which often affect the craniofacial region and cause significant functional and aesthetic impairments. This report presents long-term surgical management of a patient with hemifacial diffuse PNF, complicated by the emergence of a rapidly enlarging midfacial tumor.
Case Report: The patient was treated for hemifacial invasive diffuse plexiform neurofibroma.
Therapeutic drug monitoring of selumetinib in pediatrics: a combined LC-MS/MS and LC-HRMS approach.
Front Pharmacol
August 2025
Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of plexiform neurofibromas (PNs), benign yet potentially debilitating tumors with limited treatment options. Selumetinib, a selective MEK1/2 inhibitor, has emerged as a targeted therapy for symptomatic, inoperable PNs in pediatric NF1 patients. Individual variability in drug metabolism, largely influenced by CYP450-mediated pathways, can affect treatment response.
View Article and Find Full Text PDF